MA38698A1 - Système d'administration transdermique - Google Patents

Système d'administration transdermique

Info

Publication number
MA38698A1
MA38698A1 MA38698A MA38698A MA38698A1 MA 38698 A1 MA38698 A1 MA 38698A1 MA 38698 A MA38698 A MA 38698A MA 38698 A MA38698 A MA 38698A MA 38698 A1 MA38698 A1 MA 38698A1
Authority
MA
Morocco
Prior art keywords
buprenorphine
sensitive adhesive
adhesive layer
acid
pressure
Prior art date
Application number
MA38698A
Other languages
English (en)
Other versions
MA38698B1 (fr
Inventor
Thomas Hille
Gabriel Wauer
Frank Seibertz
Shu-Lun Weinheimer
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51022809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MA38698A1 publication Critical patent/MA38698A1/fr
Publication of MA38698B1 publication Critical patent/MA38698B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
    • A61F13/0256—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the parametric properties of the adhesive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un système thérapeutique transdermique pour l'administration transdermique de buprénorphine, comprenant une structure de couche auto-adhésive contenant de la buprénorphine comprenant a) une couche de support imperméable à la buprénorphine et b) une couche adhésive sensible à la pression contenant de la buprénorphine sur ladite couche de support imperméable à la buprénorphine, la couche adhésive comprenant a) au moins un adhésif sensible à la pression à base de polymère, b) une quantité efficace de façon analgésique de base de buprénorphine ou d'un sel pharmaceutiquement acceptable de celle-ci, c) une substance augmentant la viscosité dans une quantité d'environ 0,1 % à environ 8 % de ladite couche adhésive sensible à la pression contenant de la buprénorphine et d) un acide carboxylique choisi dans le groupe consistant en acide oléique, acide linoléique, acide linolénique, acide lévulinique et leurs mélanges, dans une quantité suffisante de telle sorte que ladite quantité efficace de façon analgésique de buprénorphine y est solubilisée pour former un mélange comprenant ladite substance augmentant la viscosité, et le mélange contenant l'acide carboxylique, la buprénorphine et la substance augmentant la viscosité formant des dépôts dispersés dans ledit adhésif sensible à la pression, et ladite couche adhésive sensible à la pression contenant de la buprénorphine étant la couche de contact avec la peau.
MA38698A 2013-06-04 2014-06-04 Système d'administration transdermique MA38698B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361830975P 2013-06-04 2013-06-04
PCT/EP2014/061567 WO2014195352A1 (fr) 2013-06-04 2014-06-04 Système d'administration transdermique

Publications (2)

Publication Number Publication Date
MA38698A1 true MA38698A1 (fr) 2017-02-28
MA38698B1 MA38698B1 (fr) 2017-10-31

Family

ID=51022809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38698A MA38698B1 (fr) 2013-06-04 2014-06-04 Système d'administration transdermique

Country Status (34)

Country Link
US (6) US20160008294A1 (fr)
EP (2) EP2810646B1 (fr)
JP (1) JP6559121B2 (fr)
KR (1) KR102302505B1 (fr)
CN (1) CN105377245B (fr)
AP (1) AP2015008920A0 (fr)
AR (1) AR096521A1 (fr)
AU (1) AU2014276910B2 (fr)
BR (1) BR112015029920A2 (fr)
CA (1) CA2914425C (fr)
CL (1) CL2015003377A1 (fr)
CR (1) CR20150647A (fr)
CY (1) CY1118054T1 (fr)
DE (1) DE112014002664T5 (fr)
DK (1) DK2810646T3 (fr)
EA (1) EA201592246A1 (fr)
ES (1) ES2599802T3 (fr)
GB (1) GB2529789A (fr)
HK (1) HK1222135A1 (fr)
HU (1) HUE031662T2 (fr)
LT (1) LT2810646T (fr)
MA (1) MA38698B1 (fr)
MX (1) MX362614B (fr)
NI (1) NI201500170A (fr)
PE (1) PE20160002A1 (fr)
PH (1) PH12015502550A1 (fr)
PL (1) PL2810646T3 (fr)
PT (1) PT2810646T (fr)
SG (1) SG11201509218SA (fr)
SI (1) SI2810646T1 (fr)
TN (1) TN2015000493A1 (fr)
TW (1) TW201509416A (fr)
WO (1) WO2014195352A1 (fr)
ZA (1) ZA201509309B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EA201491164A1 (ru) 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
AP2015008920A0 (en) 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
CA2948219C (fr) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Methode de regulation de liberation d'agent actif dans un systeme d'administration transdermique
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CN106456566B (zh) 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
CA3104099A1 (fr) 2015-03-10 2016-09-15 Rhodes Technologies Sel d'acetate de bruprenorphine et procedes pour la preparation de bruprenorphine
EP3349737A4 (fr) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC Système d'administration transdermique
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
US10486690B2 (en) * 2016-12-14 2019-11-26 Bendix Commerical Vehicle Systems, Llc Front end motor-generator system and hybrid electric vehicle operating method
EP3558276B1 (fr) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine et du polysiloxane ou du polyisobutylène
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
US20180221297A1 (en) * 2017-02-03 2018-08-09 Kirti H. Valia System and Method for Improving Adhesion of Transdermal Delivery Devices
WO2019002204A1 (fr) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Système thérapeutique transdermique contenant de l'asénapine et un polymère hybride acrylique de type silicone
US12383509B2 (en) 2017-09-04 2025-08-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an emulsifier
WO2019064026A1 (fr) 2017-09-29 2019-04-04 Orexo Ab Nouvelles compositions pharmaceutiques
WO2019166572A1 (fr) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Système pharmaceutique pour l'administration transdermique d'un inhibiteur de la c1 estérase
US20210000755A1 (en) * 2018-03-13 2021-01-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
CA3097189A1 (fr) * 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Dispositif d'administration transdermique de tetrabenazine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US20240285546A1 (en) * 2019-12-20 2024-08-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing agomelatine
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA2002299A1 (fr) 1988-11-10 1990-05-10 Eugene G. Drust Composes pour l'administration transdermique de sels de buprenorphine
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
DE3939376C1 (fr) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
CN1195505C (zh) 1999-07-02 2005-04-06 Lts勒曼治疗系统股份公司 以聚硅氧烷及亲两性溶剂为基础的微贮存系统
DE19958554C2 (de) 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (fr) 2001-02-16 2002-10-24 Grünenthal GmbH Utilisation de la buprenorphine pour la production de systemes de delivrance transdermique servant au traitement de l'incontinence urinaire, et specialement de l'incontinence urinaire due a l'urgence urinaire
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
AU2002350207A1 (en) * 2001-11-19 2003-06-10 Control Delivery Systems, Inc. Topical delivery of codrugs
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
EP1526848B1 (fr) 2002-08-09 2007-07-18 Grünenthal GmbH Antagonistes du recepteur opioide dans des systemes transdermiques a base de buprenorphine
US20050191340A1 (en) 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
CN100512806C (zh) * 2003-04-14 2009-07-15 Lts勒曼治疗系统股份公司 具有包含辣椒碱的聚硅氧烷基质的治疗贴剂
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8007737B2 (en) * 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
DE102006026578B4 (de) 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
JP5235384B2 (ja) 2007-11-08 2013-07-10 リンテック株式会社 貼付シート
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2366388A1 (fr) * 2010-03-17 2011-09-21 Ratiopharm GmbH Système thérapeutique transdermique non occlusif destiné à l'administration de buprenorphine
AU2011331511C1 (en) * 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
AP2015008920A0 (en) 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system

Also Published As

Publication number Publication date
PL2810646T3 (pl) 2017-02-28
CY1118054T1 (el) 2017-06-28
GB201522307D0 (en) 2016-02-03
BR112015029920A2 (pt) 2017-07-25
US20200237748A1 (en) 2020-07-30
CN105377245A (zh) 2016-03-02
TN2015000493A1 (en) 2017-04-06
MX362614B (es) 2019-01-28
AR096521A1 (es) 2016-01-13
DE112014002664T5 (de) 2016-04-07
MX2015016123A (es) 2016-07-21
JP2016520638A (ja) 2016-07-14
AU2014276910B2 (en) 2017-03-09
ES2599802T3 (es) 2017-02-03
US20160008294A1 (en) 2016-01-14
KR20160014064A (ko) 2016-02-05
PE20160002A1 (es) 2016-01-23
AP2015008920A0 (en) 2015-12-31
ZA201509309B (en) 2017-11-29
US20170128384A1 (en) 2017-05-11
US20180092905A1 (en) 2018-04-05
PH12015502550A1 (en) 2016-02-22
HK1204766A1 (en) 2015-12-04
US11529345B2 (en) 2022-12-20
HK1222135A1 (zh) 2017-06-23
CN105377245B (zh) 2018-07-17
PT2810646T (pt) 2016-10-05
EP2810646B1 (fr) 2016-07-27
CR20150647A (es) 2016-02-19
GB2529789A (en) 2016-03-02
DK2810646T3 (en) 2016-10-31
SG11201509218SA (en) 2015-12-30
SI2810646T1 (sl) 2016-11-30
TW201509416A (zh) 2015-03-16
MA38698B1 (fr) 2017-10-31
EP3106153A1 (fr) 2016-12-21
KR102302505B1 (ko) 2021-09-15
JP6559121B2 (ja) 2019-08-14
AU2014276910A1 (en) 2016-01-28
HUE031662T2 (en) 2017-07-28
US20200316055A1 (en) 2020-10-08
WO2014195352A1 (fr) 2014-12-11
US20160101100A1 (en) 2016-04-14
NI201500170A (es) 2016-08-05
CA2914425A1 (fr) 2014-12-11
EP2810646A1 (fr) 2014-12-10
CA2914425C (fr) 2019-09-17
LT2810646T (lt) 2016-10-25
CL2015003377A1 (es) 2016-06-17
EA201592246A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
MA38698B1 (fr) Système d'administration transdermique
Panlilio et al. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction
BR112014014137A2 (pt) sistema de liberação transdérmica compreendendo buprenorfina
TN2015000201A1 (en) Transdermal delivery system
MX382132B (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno
EA201500553A1 (ru) Многодневный пластырь для чрескожного введения ротиготина
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA38949A1 (fr) Forme saline d'hydrochlorure pour inhibition d'ezh2
EP4238580A3 (fr) Systeme d'administration transdermique comprenant un mediateur d'interface
RU2014102937A (ru) Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
CL2019000753A1 (es) Composición farmacéutica que comprende antagonista de receptor mineralocorticoide y su uso.
RU2014102938A (ru) Композиция вакцины для трансдермального введения
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
MA53418B1 (fr) Préparation d'absorption transdermique contenant du donépézil stabilisé
EP3973969A4 (fr) Composition pour la prévention ou le traitement du cancer, contenant, en tant que principe actif, des vésicules extracellulaires exprimant l'il-2 en surface
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
JP2012520829A5 (fr)
EP2101809A4 (fr) Composition pharmaceutique contenant de l'arazyme et destinée à prévenir des troubles hépatiques
Chang et al. The Exploration of Pathophysiologic Mechanisms and Therapeutic Strategy for Diabetes and Hypertension Induced Erectile Dysfunction
MA38310A1 (fr) Combinaison médicamenteuse comprenant la phényléphrine et le paracétamol
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA42361A1 (fr) Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one
RU2010136364A (ru) Способ лечения алкогольной, никотиновой, наркотической и иных форм зависимостей